DexCom, Inc. vs National Beverage Corp. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while National Beverage Corp. trades at $30.52 (market cap $2.89B). The key difference: DexCom, Inc. is far larger — about 11× National Beverage Corp.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and National Beverage Corp. for 33 Days on average.
| DXCM | FIZZ | |
|---|---|---|
Market Cap | $31.86B | $2.89B |
Volume | 3,607,070 | 553,950 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $37.73 |
52-Week Low | $54.84 | $29.20 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.32B | $2.84B |
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
National Beverage Corp. (FIZZ) trades at $30.84, up 4.19% today, showing bullish technical signals despite recent earnings misses. The company maintains solid fundamentals with $1.2B revenue, 14.81% net margin, and strong ROE of 40.13%, though growth has stalled with flat revenue trends. Recent news highlights margin pressure from input costs and a special $3.25 dividend payment in July 2026.
Outlook remains cautious with 50% analyst sell ratings reflecting growth concerns, while technical strength near support at $30 offers short-term stability. Key risks include persistent margin compression and competitive pressures in the beverage sector, though valuation at 16.58 P/E appears reasonable for current earnings power.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →